VEGFA and prostate cancer: In addition to direct anti-proliferative and anti-invasive activities, GV1001 treatment suppressed mitogen-induced expression and secretion of VEGF in A59 cells, but not in H1299 cells (Fig. 7C and D), similar to previous reports that GV1001 suppresses the expression of VEGF in renal and prostate cancer cells [22,46].